33 results about "High affinity receptor" patented technology

The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognising the native signal molecule(s). By binding to signalling molecules, the receptors reduce and maintain extra-cellular concentrations of signal molecules below the threshold level that would otherwise result in certain opportunistic pathogens adopting a virulent form, and can transform virulent organisms to non-virulent states. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease monitoring and management, and in related applications where the host for infection is an animal or plant.

The invention relates to an artificial transcription factor comprising a polydactyl zinc finger protein targeting specifically a receptor gene promoter fused to an inhibitory or activatory protein domain, a nuclear localization sequence, and a protein transduction domain. In particular examples these receptor gene promoters regulate the expression of the endothelin receptor A, the endothelin receptor B, the Toll-like receptor 4 or the high-affinity IgE receptor. Artificial transcription factors directed to the endothelin A or B receptors are useful in the treatment of diseases modulated by endothelin, such as cardiovascular diseases, and, in particular, eye diseases, e.g. retinal vein occlusion, retinal artery occlusion, macular edema, optic neuropathy, central serous chorioretinopathy, retinitis pigmentosa, Leber's hereditary optic neuropathy, and the like. Artificial transcription factors directed to the Toll-like receptor 4 or the IgE receptor are useful for the treatment of autoimmune disorders, and the like, and allergic disorders, respectively.

Contemplated immunotherapies include co-administration of an activated NK cell that is further genetically modified and a cancer therapeutic agent. In preferred embodiments, activated NK cells are further modified to taNK cells, which include a chimeric antigen receptor (CAR) with affinity for a cancer specific antigen, a cancer associated antigen, or a tumor specific antigen. Activated NK cells can also be further genetically modified to include high affinity Fc receptor CD16a (V158). Appropriate cancer therapeutic agents include chemotherapeutic drugs (e.g., nant-paclitaxel) or cancer targeted antibodies (e.g., trastuzumab).

The invention relates to a single chimeric converter for a T-cell signal and application thereof, which belongs to the fields of molecular biology and immunology. Specifically speaking, the single chimeric converter is formed by connection of a polypeptide highly efficiently bonding with immunosuppression molecules on the surfaces of tumor cells and / or tumor matrix cells to a transmembrane domain originated from a high-affinity receptor and an intracellular peptide fragment of a costimulatory signal molecule through a hinge structure. Out-membrane polypeptide receives a signal of the immunosuppression molecules on the surfaces of tumor cells and / or tumor matrix cells and transmits the signal into a cell, a second signal of immune cells is activated through the intracellular peptide fragment of the costimulatory signal molecule, so multiplication capacity of the immune cells and the secretion function of cell factors are enhanced, and the survival time of the activated immune cells is prolonged; thus, side-effects of a tumor immunosuppression microenvironment on adoptive cell therapy effector cells are overcome.

A cyclohexane derivative as shown by formula IB or a stereoisomer or a salt thereof, has a high affinity for D3 receptors and 5-hydroxytryptamine, has a lower affinity for D2 receptors, shows a high selectivity for D3 / D2 receptors, and can be used as a therapeutic drug against neuropsychiatric diseases.wherein; X is N or CH; R isR is optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I and C1-C6 alkyl; and the C1-C6 alkyl is optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, and I.

Provided is an Fc fusion high affinity IgE receptor α-chain having excellent stability at low pH. An Fc fusion protein comprising:(i) a high affinity IgE receptor α-chain; and(ii) an Fc region of IgG1, whereina linker fragment region between the (i) and the (ii) is the amino acid sequence shown in SEQ ID NO: 2.

The invention belongs to the technical field of drug molecular model building, and in particular relates to a method for building a high-throughput drug screening model based on the ICAM-1 signaling pathway. ICAM‑1 is an important immune system component and an important characterization molecule in many diseases. The present invention focuses on the ICAM-1 molecule and its regulatory network, uses engineered yeast as a medium to construct a novel drug screening system, displays the ICAM-1 high-affinity receptor LFA-1 insertion domain on the surface of the yeast and expresses green in its cells fluorescent protein. If the drug acts on ICAM-1 and its signaling pathway, it will affect the number of yeast cells and unit animal cells. Drugs can be quickly screened through the difference in fluorescence intensity. The fluorescence intensity of yeast can be used to achieve efficient, simple, and efficient detection of ICAM-1 expression. Economical high-throughput drug screening. The present invention has high plasticity, and respective drug screening platforms can be established according to animal cells of different disease types.